It makes the most sense, particularly with the fac
Post# of 22755
But a lot would really depend on the success of REMOXY I would imagine -- which is what we're all waiting for.. The stock has done nothing but tumble since the failed FDA approval for this drug. To me, this indicates that (if/when) the next round is announced, there will be a lot more skeptics involved and the price's move upwards will not be as dramatic...
They are anticipating the final studies to be completed by year-end 2017, so I'm still holding out for that...
Who knows, maybe $PFE will buy them back?
If end of year announcements don't yield $10+/share pricing - we may be having some divorces to deal with soon